Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals
Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.
Authors
- Varsha Sharma (ORCID: https://orcid.org/0000-0002-7459-5428)
- Niklas Magnell
- L Jäger (ORCID: https://orcid.org/0000-0003-3000-3686)
- Riccarda Delfino
- Jane Horne (ORCID: https://orcid.org/0000-0003-0985-8110)
- Nadia Godin-Heymann (ORCID: https://orcid.org/0000-0003-3260-0302)
- Michael Jones (ORCID: https://orcid.org/0000-0001-5215-2346)
- Richard Bryce (ORCID: https://orcid.org/0000-0002-1507-9650)
- M. Ratcliffe
- Dany Bell
- Kenneth W. Walls
- David Shera
- Rosie Mughal
Institutions
- Macmillan Cancer Support (GB)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Poland) (PL)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1080/14796694.2025.2535098
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- AstraZeneca